The studies included in this review applied gene therapy for T1D in multiple modalities and demonstrated preservation of pancreatic β-cells, thus optimizing insulin secretion levels, while few studies also focused on sustaining this reference range insulin secretion for months, contributing to look about the long-term benefits. This evidence concerns the gene INS and type 1 diabetes mellitus.